| Rituximab therapy for Type I membranoproliferative glomerulonephritis. | |
| | |
MedLine Citation:
|
PMID: 22445472 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Aims: Type I membranoproliferative glomerulonephritis (MPGN) is an immune-complex disease with a relatively poor prognosis. It has no established treatment in adults. Our hypothesis was that this disease would respond to B cell depletion with rituximab, an anti-CD20 monoclonal antibody. Methods: We conducted an openlabel trial, in Canada and the United States, of rituximab in 6 adult patients with Type I MPGN (4 idiopathic, 2 with cryoglobulinemia). The rituximab dose was 1,000 mg intravenously on Day 1 and on Day 15. The patients were followed for 1 year. The primary outcome was the change in proteinuria. Results: Peripheral blood B cells were suppressed, after rituximab, in all patients. The mean urinary protein excretion was 3.9 ± 2.0 g/d before treatment. Proteinuria fell in all patients, at all-time points, after rituximab administration. The difference was statistically significant (p < 0.05) at 6, 9 and 12 months, but not at 3 months. The minimum mean urinary protein excretion was 1.4 ± 1.4 g/d at 9 months. There were 2 complete and 3 partial remissions among the 6 patients. The creatinine clearance did not change significantly over the course of the study. There were no adverse effects. Conclusions: Rituximab reduced proteinuria among patients with Type I MPGN. This trial suggests that B cells may play a role in this disease and that additional study of B-cell suppression is warranted. |
| | |
Authors:
|
John J Dillon; Michelle Hladunewich; William E Haley; Heather N Reich; Daniel C Cattran; Fernando C Fervenza |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical nephrology Volume: 77 ISSN: 0301-0430 ISO Abbreviation: Clin. Nephrol. Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-03-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0364441 Medline TA: Clin Nephrol Country: Germany |
Other Details:
|
Languages: eng Pagination: 290-5 Citation Subset: IM |
Affiliation:
|
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA, Toronto Glomerulonephritis Registry, University of Toronto, Toronto, Ontario, Canada and Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Renal histology in patients with elevated serum creatinine and concurrent normal urinalysis.
Next Document: Evaluation of T-Cell receptor diversity in pediatric patients with minimal change nephrotic syndrome...